← All trials
NCT05659992
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2022
- Primary completion
- Jan 10, 2024
- Completion date
- Jan 10, 2024
- First posted
- Dec 21, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- People's Liberation Army of ChinaLead sponsor
- People's Liberation Army of ChinaReponsible party - principal investigator
- People's Liberation Army of ChinaStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.